26eP Trastuzumab deruxtecan in HER2-positive or ERBB2-mutated tumours: Real-world clinical practice data

Read full text Summarise with VIRAT
Authors: Noemy Rodriguez Macias, M.A. Cordero, J. Montes González, C. Saavedra Serrano, M.L. Sanchez Lorenzo, R. Sánchez Bayona, J. Moreno, L. Montero de la Fuente, Alfonso Gómez de Liaño, D. Rodriguez Abreu, P. Soto Rojas, A. Estival González
+7 more E.G. Guadalupe, N. Karani Narain, J.A.R. Rodríguez García, E.F. Llabres Valenti, Guillermo Visedo, M.G. Arevalo, Avinash Ramchandani Vaswani
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Trastuzumab deruxtecan (T-DXd) is a HER2-directed antibody-drug conjugate approved for HER2-positive breast and gastric cancer, and for ERBB2-mutated non-small-cell lung. Phase II trials (Destiny-PanTumour01 and -02) have reported antitumour activity in other HER2-overexpressing or ERBB2-mutated malignancies. However, evidence in actual clinical practice is limited.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations Gastric Cancer Management and Outcomes

Publication details

Journal / source
ESMO Open
Volume
11
Pages
106129–106129
Publication date
1 April 2026
Language
EN